Joel Plumas

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Alain Oncologie Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands.

Cerhum SA engages in the manufacture of dental equipment and supplies. Its products include MyBone and technical ceramics. It offers bone graft and dental printing, ceramic and plastic prototyping, small series production, three dimensional scanning services. The company was founded by Grégory Nolens and Caroline Remacle in 2015 and is headquartered in Liege, Belgium.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

The European Vaccine Initiative manufactures vaccines. The private company is based in London, UK.

Henogen SA develops and manufactures biopharmaceuticals. The company was founded on November 19, 1999 and is headquartered in Charleroi, Belgium.

Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.

Bridge2Health SA provides biomedical translational research services. It offers services to the clinicians, basic researchers and pharmaceutical industries. The firm also provides blueprint for biobank query and retrieval between universities. The company was founded in September 2012 and is headquartered in Liege, Belgium.

Ad Bio Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden.

ANALIS manufactures and distributes instruments and furniture for laboratories. The private company is based in Namur, Belgium. and has subsidiaries in France. The Belgian company was founded in 1927. Vincent Luyckx has been the CEO of the company since 2016.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Pavilion Data Systems, Inc. designs and develops NVMe-oF storage technologies. Its NVMe-over-Fabric Storage Array ingests, processes, stores, and serves an order of magnitude more data for massively-parallel, modern applications. The company was founded by Kiran Malwankar, V. R. Satish, and Sundar Kanthadai in 2014 and is headquartered in San Jose, CA.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. Celleron has deep relationships with Oxford University and is located on the Oxford Science Park. The British company focuses on the clinical development of new and innovative therapies to treat cancer. Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The company's lead products are currently in clinical trials, and they have a biomarker platform that allows them to identify responsive patients. Celleron Therapeutics Ltd. was founded in 2004, and the CEO is Nick la Thangue.

Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.